33 results about "Cervical carcinoma" patented technology

The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.

The invention discloses a strain of Shenjing pig combined lactobacillus and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31452. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age and is sensitive to various common antibiotics, and fermented supernate of the strain shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, salmonella paratyphi B and gardnerella vaginalis; the compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

The invention discloses a lactobacillus jensenii strain and application thereof in fermentation of wall-broken ganoderma lucidum spore powder. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.31484. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is sensitive to various common antibiotics, and has strong lactic acid production capacity; a fermentation supernatant of the bacillus subtilis shows relatively strong inhibition capability on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae, yersinia enterocolitica and gardnerella vaginalis, and has relatively strong adhesion capability, growth inhibition capability and apoptosis promotion effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of amino acid and bioactive substances such as peptides, arachidonic acids, steroids and polyketones can be greatly increased, the strain has an obvious inhibition effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in biological agents, but also opens up a new way for combined application of lactic acid bacteria and ganoderma spores.

The invention belongs to the technical field of gene methylation detection, and particularly relates to a cervical cancer related gene methylation detection kit and system, which comprises primers and probes for detecting APC, CALCA, DAPK and ESR1 gene methylation, primers and probes for monitoring internal control genes, a PCR reaction liquid, a positive quality control product and a negative quality control product, the use method comprises the following steps: 1) performing nucleic acid extraction on a sample; (2) converting the extracted genome DNA by bisulfite; (3) premixing and subpackaging the gene methylation detection reagent to obtain a PCR reaction system; (4) adding the DNA obtained in the step (2) into the PCR reaction system in the step (3), uniformly mixing, and carrying out PCR amplification; 5, gene methylation interpretation is carried out after the reaction is ended, the method has the advantages of being high in sensitivity, low in cost, easy and convenient to operate, short in detection period, visual in interpretation and the like, and methylation of the cervical cancer related genes can be rapidly and accurately detected.

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.

The invention discloses a construction method and application of an animal model for HPV (human papillomavirus) pathogenic mechanism research, and belongs to the technical field of animal models. According to the construction method of the HPV fixed-point integration animal model, HPV16 gene knock-in is carried out on the Col1a1 gene locus of a C57BL / 6J mouse through CRISPR / Cas mediated genome engineering. The method comprises the following steps: (1) designing specific gRNA; (2) constructing a knock-in vector Donor vector; and (3) uniformly mixing Cas9 protein, gRNA and a targeting vector Donor vector to obtain an injection compound, performing micro-injection on the injection compound into a mouse fertilized egg, and sending the injection compound back to a pregnant mouse fallopian tube to cultivate offspring so as to generate a gene knock-in mouse. The animal model prepared by the method can be used as a contrast of a cervical cancer precancerous lesion animal model for scientific research.

The application discloses a series of derivatives based on natural product gelsemium methyl, pharmaceutically acceptable salts and preparation methods thereof. Bioactivity tests show that the compounds have the effect of inhibiting the proliferation of various tumor cells. The compounds can be used for the treatment of various cancers (including but not limited to gastric cancer, liver cancer, lung cancer, esophageal cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, nasopharyngeal cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer and skin cancer) as active pharmaceutical ingredients.

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

An irradiation device and a treatment method capable of effectively irradiating an antibody-photosensitive substance bound to a cell membrane of cervical cancer with near-infrared light. The treatment method for cervical cancer includes: intravenously administering an antibody-light-absorbing substance; inserting a second irradiation device including a second optical fiber from a vagina into a cervix 12 hours to 36 hours after the intravenous administration; performing irradiation by using the second optical fiber included in the second irradiation device in a direction substantially perpendicular to the second optical fiber; drawing at least a part of a deformation portion included in the second irradiation device to an external uterine ostium and inflating the deformation portion so as to follow a shape of an organ; emitting near-infrared light by using the second optical fiber in a substantially distal direction and / or the direction substantially perpendicular to the second optical fiber; and contracting the deformation portion.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.

The invention belongs to the technical field of gene detection, and discloses application of EVX2 gene methylation in evaluation of cervical carcinoma risk of high-risk HPV infected persons. The biomarker for evaluating the cervical cancer risk of the high-risk HPV infected person is a methylation site of an EVX2 gene. According to the invention, detection of the methylation level of the EVX2 gene is applied to evaluation of cervical cancer risk of high-risk HPV infected people, and the kit can be used for screening and shunting cervical HSIL and cervical cancer and is beneficial to early intervention of high-risk HPV infected people.

The invention discloses a data processing device for grouping or auxiliary grouping of cervical cancer occurrence risks of subjects, and belongs to the technical field of medical care informatics. The technical problem to be solved by the application comprises how to group subjects according to the occurrence risk of cervical cancer. Therefore, the application provides a device comprising the following modules: A1) a data receiving and analysis processing module which is used for receiving GPRC5A gene expression quantity data of a test queue to obtain a judgment threshold value of the occurrence risk of the cervical cancer; a2) a data input module used for inputting sample data, wherein the sample data is GPRC5A gene expression quantity data of a subject; and A3) a data comparison and result output module, which is used for comparing the sample data with the determination threshold value, and grouping the cervical cancer occurrence risk of the subject according to the comparison result. The application discloses the effect of the GPRC5A gene in diagnosis or auxiliary diagnosis of cervical cancer for the first time.

The present invention provides an anti-PD-1 antibody comprising a pembrolizumab complementarity-determining region (CDR) and an antibody-drug conjugate combination that binds to tissue factor (TF), the antibody-drug conjugate (such as tisotumab vedotin) comprising monomethyl auristatin E and the CDR of tisotumab, and provides the use of methods thereof for treating cancers (such as breast cancer and cervical cancer). The present invention also provides a composition and a kit for treating cancers (such as breast cancer and cervical cancer), the composition and the kit comprising an anti-PD-1 antibody and an antibody-drug conjugate that binds to TF, the anti-PD-1 antibody comprising the CDR of pembrolizumab, and the antibody-drug conjugate (such as tisotumab vedotin) comprising monomethyl auristatin E and the CDR of tisotumab.

The present invention discloses a molecular marker combination for predicting the prognosis of patients with cervical cancer and its application. The present invention uses the three NRGs screened including CHMP4C, SLC25A5 and VDAC1 as a molecular marker combination, establishes a risk prediction model with 3 NRGs, and divides cervical cancer patients into high-risk and low-risk groups. The risk prediction model in the present invention has an AUC value of 0.694 when predicting a 1-year survival period, an AUC value of 0.703 when predicting a 3-year survival period, and an AUC value of 0.664 when predicting a 5-year survival period, which has better accuracy and specificity. And the predictive performance of the risk prediction model in the present invention has been verified in the validation set. The model in the present invention can effectively predict the prognosis of patients with cervical cancer, which is helpful for the selection of clinical treatment plans, and thus realizes early intervention and early treatment of cervical cancer.

Disclosed herein are antibody drug complexes comprising a drug unit coupled to an antibody capable of binding to TROP2 or an antigen-binding fragment thereof, and methods of using the antibody drug complexes. The methods of use include, but are not limited to, cancer treatment and detection. The antibody drug complexes disclosed herein can bind to specific cancer cell surfaces. Exemplary targets of the antibody drug complexes disclosed herein include epithelial cancers, such as lung cancer, breast cancer, head and neck cancer, esophageal cancer, gastric cancer, bladder cancer, pancreatic cancer, colorectal cancer, cervical cancer, endometrial cancer, ovarian cancer, laryngeal cancer, prostate cancer, thyroid cancer, and oral cancer.

The present disclosure relates to methods, combinations and uses for the treatment of cervical cancer using an anti-PD-L1 binding protein or an anti-PD-1 binding protein and chemoradiotherapy.

The invention discloses a cervix sampler, an operation method thereof and a kit, the sampler comprises a shell, the shell comprises a shell side wall and a closed shell far-end wall, the shell side wall comprises a first notch, and the first notch is arranged close to the shell far-end wall; the sampling brush is configured to be accommodated in the shell, and at least one part of the sampling brush is exposed to the position of the first notch in at least one use state; the shaft comprises a shaft far end and a shaft near end, the shaft far end is connected with the sampling brush, the shaft near end further comprises an operator, and the operator drives the shaft and the sampling brush to rotate in the circumferential direction under the operation of external force, so that the sampling brush makes contact with a target sample near the first notch in the using state, and friction force is generated to obtain biological tissue. The sampler can be conveniently placed at a target position and sample tissue can be conveniently obtained. The collected biological tissues can be cervical cells, and can be used for double detection (PAP / HPV Co-Testing) of cervical smear (PAP) and human papilloma virus (HPV), and can be used for screening cervical cancer.

The present invention discloses a dipeptide compound with anticancer activity and a preparation method thereof. The dipeptide compound is a compound shown in formula I. The compound has anticancer activity, and in particular shows obvious anticancer activity against lung cancer, colon cancer, cervical cancer and / or liver cancer.

The utility model relates to a condom device worn on a mouth, a lip and a tongue, which is an integrally formed long sheet type high-density elastic film body and can be hung on the mouth, the lip and the tongue, two side edges extend to the back of the back of the head and the neck, and two sides of two ends are respectively provided with a hole of a hook buckle so as to hook the long sheet type high-density elastic film body of the condom. The front mouth, lip and tongue position of the long sheet type high-density elastic film body is designed to be of a protruding three-dimensional bag-shaped space structure, the tongue can stretch out of the protruding three-dimensional bag-shaped space structure and can flexibly move up, down, left and right and suck and lick, and the surface layer is provided with protruding three-dimensional small-particle lines and concave-convex lines besides the smooth surface, so that the mouth, the lip and the tongue of the long sheet type high-density elastic film body is not prone to falling off. When the device is used in the relation, direct contact of body fluid and secretions of sexual objects can be blocked, infection of various venereal diseases and invasion of human mastoid HPV viruses are avoided, diseases, oral esophageal cancer and cervical cancer are prevented, and safe life is created.

The invention discloses a prognosis model for predicting cervical cancer based on autophagy-related genes and a construction method of the prognosis model, and belongs to the technical field of biomedicine. The model contains four characteristic genes related to prognosis of cervical cancer: BCL2, SPNS1, TM9SF1 and TP73, and the characteristic genes can become biological markers related to cervical cancer; the calculation formula of the prognosis model is as follows: risk score = (-0.411 * BCL2 gene expression quantity) + (0.753 * SPNS1 gene expression quantity) + (0.669 * TM9SF1 gene expression quantity) + (-0.398 * TP73 gene expression quantity). The prognosis model provided by the invention can evaluate the prognosis of the cervical cancer patient, improve the prognosis prediction capability of the cervical cancer patient, effectively identify the high-risk patient, assist in predicting the curative effect of immunotherapy, detect and intervene the high-risk patient earlier in clinic, improve the survival rate and life quality of the patient, and improve the clinical application prospect. A reference is provided for individualized diagnosis and treatment of cervical cancer; and tests and external verification prove that the model is stable and effective.

The present application relates to the technical field of drug synthesis, in particular to a benzylurea compound, a preparation method and application thereof. The structural formula of the benzylurea compound is shown in the following: wherein R1 represents any one of a connecting bond, a substituted or unsubstituted amide bond and a C1-C10 unsubstituted alkyl bond, and R2 is selected from any one of a substituted or unsubstituted single aromatic heterocyclic group, or a substituted or unsubstituted single aromatic ring group, or a substituted or unsubstituted benzo-fused ring group. The benzylurea compound can effectively inhibit the activity of tumor cells, and has a good therapeutic effect on esophageal cancer, lung cancer, gastric cancer, breast cancer, colorectal cancer, laryngeal cancer, nasopharyngeal cancer, oral cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, lymphoma, acute leukemia, osteosarcoma, Ewing's sarcoma and thyroid cancer.

The invention relates to the technical field of cervical lesions, and discloses a cervical lesion risk prediction model based on combination of double gene methylation and clinical characteristics and application thereof, and the method comprises the following steps: S1, selecting a research object; s2, carrying out double-gene methylation detection; and S3, data statistical analysis: performing statistical analysis by applying SPSS 25.0 and R4.1. 2 software, performing chi-square test and single-factor logistic regression analysis on each potential influence factor, and bringing the screened influence factors into multi-factor logistic regression analysis. According to the cervical lesion risk prediction model based on combination of double-gene methylation and clinical characteristics and application and development thereof, evidence-based basis can be better provided, clinical reduction of missed diagnosis and misdiagnosis rates of cervical cancer is helped, morbidity and mortality are reduced, and implementation of a strategic target of eliminating cervical cancer in China is assisted.

The invention discloses a construction method and application of a human vaginal flora 16S rRNA gene V4 region sequence database, and the construction method mainly comprises the following steps: (1) retrieving and downloading 16S rRNA sequences in the database, (2) carrying out sequence comparison and correction, (3) constructing a human vaginal flora 16S rRNA full-length database, (4) obtaining human vaginal flora 16S rRNA gene V4 region fragments, and (5) constructing the human vaginal flora 16S rRNA gene V4 region sequence database. (5) forming a V4 region sequence database of the human vaginal flora 16S rRNA gene; based on the construction method, the human vaginal flora is identified, community type classification is carried out, and a new community type is named as CST6. Human vaginal flora detection can be annotated to the genus or species level, the diversity and richness of the human vaginal flora are disclosed, and the data can be used for analyzing whether the human vaginal flora is disordered or not, discovering whether known pathogenic bacteria or potential pathogenic bacteria exist or not, and determining whether the human vaginal flora is disordered or not. Further, the correlation between the vaginal flora disorder and diseases such as female health conditions and cervical cancer is explored.

The invention belongs to the technical field of biomedicine, particularly relates to the field of molecular diagnosis, and more particularly relates to a kit for screening cervical canceration and application of the kit. The invention provides a biomarker for screening cervix canceration, the biomarker is at least one of an XIRP2 autoantibody, a POU3F2 autoantibody and a PCNA autoantibody, the expression level of the marker in serum of a patient with cervix canceration is obviously higher than that of a normal person, and the difference has statistical significance. The invention also provides a kit for screening cervical canceration. The kit contains an antigen for detecting the biomarker. By detecting the expression level of the biomarker in human serum, the biomarker can be used for screening and diagnosing cervical canceration.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.

The present invention discloses a biomarker and an evaluation kit for evaluating cervical cancer lymph node metastasis and its application, and relates to the field of biological detection reagents. In the present invention, we have confirmed that the EndoMT pattern of tumor-associated lymphatic vessels in metastatic cervical cancer is significantly increased compared with non-metastatic cervical cancer. CAFs promote efficient lymph node metastasis of cervical cancer by mediating and activating the EndoMT pattern of tumor-associated lymphatic vessels. Therefore, the EndoMT pattern of tumor-associated lymphatic vessels can be used as a biomarker in the preparation of a cervical cancer lymph node metastasis evaluation kit.

The invention discloses the use of a compound Parimifasor in the preparation of an anti-tumor drug, and belongs to the field of medicine. The invention finds through in vitro anti-tumor experiments that the compound Parimifasor has a broad-spectrum anti-tumor activity, and exhibits strong inhibitory activity against human glioblastoma (LN229), colon cancer (HCT-116), lung adenocarcinoma (H1299), large cell lung cancer (NCI-H460), renal clear cell carcinoma (786-O), osteosarcoma (143B), esophageal cancer (KYSE140), pancreatic cancer (PANC-1), cholangiocarcinoma (HCCC-9810), cervical cancer (Hela), hepatocellular carcinoma (HepG2), fibrosarcoma (HT-1080), gastric cancer (HGC-27), bladder transitional cell carcinoma (UM-UC-3) and melanoma (A375) cell lines, and is expected to be developed into a broad-spectrum anti-tumor drug.

This invention belongs to the field of chemical pharmaceuticals and synthesis technology, specifically relating to dihydropyrroloquinazoline spiroindole ketones, their applications, pharmaceutical compositions, and synthetic methods. The compounds provided by this invention exhibit inhibitory activity against the proliferation of HeLa and A-549 cancer cells, suggesting that these compounds could serve as active ingredients in anticancer drugs for cervical cancer, lung cancer, and other cancers. In particular, some compounds significantly inhibit the growth and proliferation of A-549, indicating the potential pharmaceutical value of these compounds and providing new structural units for drug screening. Furthermore, the synthetic method of this invention uses a one-pot synthesis of 1-(aryl)methylimine-substituted indoline compounds and 3-diazo-2-indole ketone compounds as starting materials. This synthetic method has advantages such as readily available and simple starting materials, easy operation, mild conditions, wide substrate applicability, and high atom economy.

The invention belongs to the technical field of animal models, and particularly relates to a construction method and application of an HPV fixed-point integration cervical intraepithelial neoplasia animal model. According to the preparation method of the HPV site-specific integration cervical intraepithelial neoplasia animal model, HPV16 gene knock-in is established on the Klf5 gene locus of a C57BL / 6J mouse through CRISPR / Cas mediated genome engineering. The method comprises the following steps: (1) determining a target sequence on a Klf5 site, and designing specific gRNA; (2) designing and constructing a knock-in vector Donor vector containing a homologous arm (Homology Arms, HAs), and inserting an HPV16 gene sequence into the knock-in vector; and (3) co-injecting the knock-in vector and the Cas9 / gRNA complex into a fertilized egg of a C57BL / 6J mouse for cultivation and birth to obtain the C57BL / 6J mouse. The animal model prepared by the method can simulate the normal-persistent HPV infection-cervical cancer precancerous lesion development stage of human cervix. And a credible animal model is provided for occurrence mechanism research and drug screening of precancerous lesions of cervical cancer.